Thank you, Mr. Chair. Mr. Chair, this is all by estimates because we don't know what the 2200 people -- because they haven't fell within a specific disease, so we don't know what their needs are. They may have high costs in pharmacare or medical supplies that they require but they haven't fallen under one of the specific diseases. And so these individuals, you know, we don't know until we actually get them to start applying to the program because until then, you know, that's where we're at, and so there's -- in the presentation, and I know that when we were in the briefing, and there's -- it could be -- cost us $1.3 million. If there's not a significant uptake, it could not -- you know, we could cover our costs. So there is -- it's all estimates right now, and that's why I'm saying, like, until we have the roll out and we know what people -- what services and what the needs are of the residents that haven't had access to this program. As well as the many other programs that are out there that are supplementing some of the individuals, so some of these individuals on this may have access to some types of insurances, which will offset some of those costs. We won't know that until people are actually applying to the program. Thank you, Mr. Chair.